Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most dosing/administration and hypoglycemia/bronchospasm warnings align with the provided label excerpts, but several safety statements are unsupported (e.g., specific hypoglycemia symptom list, “older infants” phrasing for bradycardia/hypotension, and “urgent medical guidance” wording), and at least one claim about missed-dose doubling is not supported. Also, monitoring scope (2 hours after initiation/increase) is not consistently reflected.
Category Scores
Accurate Statements
Hemangeol (propranolol oral solution) is used to treat infantile hemangioma.
Indications and Usage: indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy (Section 1).
Hemangeol dosing is weight-based.
Dosage and Administration: dosing expressed as mL/kg and mg/kg (Section 2).
Hemangeol dosing uses a titration schedule followed by maintenance dosing.
Section 2: start dose, increase after 1 week and after 2 weeks, then maintain for 6 months.
Hemangeol dosing is designed to start low and increase gradually over time.
Section 2: 0.15 mL/kg (0.6 mg/kg) twice daily then increased stepwise.
Hemangeol doses are taken with meals or immediately after feeding.
Section 2: administer during or right after a feeding to reduce hypoglycemia risk.
The daily dose is divided into the required number of administrations per day according to label instructions.
Section 2: twice daily dosing with at least 9 hours apart.
During the ramp-up period, the per-dose amount increases gradually until the target dose level is reached.
Section 2: increases after 1 week and after 2 weeks.
Hemangeol is given multiple doses daily according to the labeled schedule.
Section 2: twice daily dosing.
Treatment ... maintains this for 6 months.
Section 2: maintain the 0.4 mL/kg (1.7 mg/kg) twice daily for 6 months.
Once the target dose is reached, dosing typically remains at that level for the remainder of the course unless the clinician adjusts for side effects, changes in weight, or other clinical reasons.
Section 2: maintain target dose for 6 months and readjust periodically as weight increases.
Skipping meals or giving doses when the infant is not eating or is vomiting can increase risk of hypoglycemia.
Section 2: to reduce hypoglycemia risk administer during/right after feeding; skip dose if not eating or vomiting. Section 5.1: risk increased during fasting/vomiting; withhold dose.
If a dose is missed, the schedule should be resumed according to instructions in the prescribing information or clinician directions.
Section 2: skip the dose if not eating or is vomiting; label-directed dosing decisions are implied by those instructions (exact missed-dose protocol not provided in excerpt).
Hemangeol dosing requires extra caution or may be paused/adjusted for feeding problems or inability to take regular feeds.
Section 2 and 5.1: administer with/right after feeding; skip/withhold dose if not eating or vomiting; risk increased during fasting/poor intake.
Hemangeol dosing requires extra caution or may be paused/adjusted for respiratory issues like wheezing.
Section 5.3: can cause bronchospasm; interrupt in lower respiratory tract infection associated with dyspnea and wheezing.
The prescribing clinician should screen for contraindications.
Contraindications list exists (Section 4); clinical practice implication is consistent but label excerpt does not explicitly instruct screening.
Unsupported Statements
Common symptoms of hypoglycemia during propranolol treatment in infants include unusual sleepiness, poor feeding, shakiness, sweating, or lethargy.
Label excerpt lists hypoglycemia may present as seizures, lethargy, or coma; it does not list shakiness, sweating as presenting symptoms in a symptom list for hypoglycemia (Section 5.1).
Hypoglycemia risk during propranolol treatment is especially increased if a feeding is missed.
Label excerpt increases risk during fasting/poor oral intake/infection/vomiting; it does not specifically state “missed feeding” as the especially increased scenario (Sections 2 and 5.1).
Propranolol can cause slower heart rate or low blood pressure symptoms, such as unusual fatigue or dizziness in older infants.
Label excerpt describes bradycardia/hypotension and symptoms as “severe (<80 beats per minute) or symptomatic bradycardia or hypotension (systolic blood pressure <50 mmHg) occurs,” but does not specify fatigue/dizziness or “older infants” (Section 5.2).
Propranolol treatment in infants can be associated with bronchospasm or wheezing in infants prone to respiratory issues.
Label excerpt: can cause bronchospasm; do not use in asthma/history of bronchospasm; interrupt in lower respiratory tract infection associated with dyspnea and wheezing. It does not state “infants prone to respiratory issues” (Section 5.3).
Propranolol treatment in infants can cause vomiting or feeding intolerance.
Label excerpt for adverse reactions lists diarrhea and vomiting, but does not mention “feeding intolerance” (Section 6.1).
If symptoms suggest hypoglycemia, breathing trouble, or marked sleepiness, urgent medical guidance should be sought.
Label excerpt instructs withhold/discontinue and treat appropriately; it does not provide an “urgent medical guidance” directive (Sections 2 and 5.1, 5.3).
If a dose is missed, the plan is usually not to double up.
No “missed dose—do not double” instruction is present in the provided excerpts (Section 2 excerpt provided does not include a missed-dose directive beyond skipping if not eating/vomiting).
If the infant vomits soon after a dose, the clinician may advise whether to repeat the dose or wait until the next scheduled administration.
Label excerpt says skip the dose if the child is vomiting; it does not describe a scenario of vomiting “soon after a dose” with advice to repeat vs wait (Section 2 and 5.1).
If weight changes significantly during therapy, the dose often needs recalculation to keep the mg/kg dose consistent.
Label excerpt says readjust the dose periodically as the child’s weight increases, but does not say “significantly” or that recalculation is often needed (Section 2).
Hemangeol dosing requires extra caution or may be paused/adjusted with intercurrent illness, especially with reduced intake.
Label excerpt mentions increased hypoglycemia risk with infection/stress/cold and states risk increased during fasting/vomiting; it does not explicitly say pause/adjust for “intercurrent illness” beyond withhold dose under these conditions (Section 5.1).
Hemangeol dosing requires extra caution or may be paused/adjusted for certain heart rhythm or blood pressure problems.
Label excerpt provides discontinuation criteria for severe/symptomatic bradycardia/hypotension and contraindications based on HR/BP, but does not state “may be paused/adjusted” specifically for “heart rhythm problems” (Sections 4 and 5.2).
The prescribing clinician should determine whether any baseline testing or in-clinic dose escalation is needed.
Provided excerpts only state monitor heart rate and blood pressure for 2 hours after initiation or dose increases; they do not mention baseline testing or in-clinic dose escalation (Section 2).
The clinician converts weight into the total daily propranolol dose.
Label excerpt gives mg/kg and mL/kg dosing and twice daily schedule; it does not describe clinician conversion steps or use of “total daily dose” as described (Section 2).
The most accurate dosing schedule is the one in the official prescribing information for the specific Hemangeol product and strength.
This is generally plausible but is not a label statement in the provided excerpts; it is not directly supported by the supplied label text.
Propranolol can cause ... low blood pressure symptoms ... in older infants.
As above: neither “older infants” nor specific symptom examples are in the provided label excerpt (Section 5.2).
Common symptoms ... sweating ...
Section 5.1 notes adrenergic warning signs masked, particularly tachycardia, palpitations and sweating, but it does not state “sweating” as a common hypoglycemia symptom list (Section 5.1).
Contradictions
Low
AI Statement
Hemangeol dosing aims to keep the dose steady at a target amount after reaching it.
Label Reference
Section 2: maintain the target dose for 6 months but “readjust the dose periodically as the child’s weight increases.”
Low
AI Statement
If a dose is missed, the plan is usually not to double up.
Label Reference
Provided excerpts do not state missed-dose double-up instructions; therefore this may conflict with implied dosing instructions but cannot be confirmed as direct contradiction from provided text.
Important Omissions
Monitoring instruction: monitor heart rate and blood pressure for 2 hours after initiation or dose increases.
Importance:
Moderate
Discontinue criteria for severe/symptomatic bradycardia or hypotension and exact thresholds (HR <80 bpm; systolic BP <50 mmHg).
Importance:
Moderate
Contraindication thresholds and conditions (e.g., corrected age <5 weeks, weight <2 kg, asthma/history of bronchospasm, specific HR/BP thresholds, pheochromocytoma, hypersensitivity).
Importance:
Moderate
Specific hypoglycemia management language: withhold dose under fasting/vomiting conditions; discontinue if hypoglycemia develops and treat appropriately.
Importance:
Moderate
Drug interaction detail: corticosteroids may increase hypoglycemia risk; consider medications in infant and nursing mother.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related statements are partially imprecise or unsupported (e.g., specific symptom list for hypoglycemia, missed-dose doubling guidance, and omitted label monitoring/threshold discontinuation criteria). These could lead to less accurate risk recognition or less precise adherence to monitoring/discontinuation requirements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Safety/operational details are missing or not fully supported (monitoring for 2 hours after initiation/increase; specific discontinuation thresholds; missed-dose guidance; exact hypoglycemia presentation).
Suggested Improvement
Align hypoglycemia symptom language to label wording (seizures, lethargy, coma; masked warning signs). Include label monitoring window (2 hours after initiation/dose increases) and HR/BP discontinuation thresholds. Remove or rephrase unsupported missed-dose/urgent-care wording to reflect label instructions (withhold/skip/withhold dose; discontinue if hypoglycemia develops).